

Product Data Sheet

STING agonist-30

Cat. No.:HY-149267CAS No.:2951078-67-2Molecular Formula: $C_{15}H_{16}N_4O_8$ Molecular Weight:380.31

Target: STING; SARS-CoV

Pathway: Immunology/Inflammation; Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ^[1] .
In Vitro	STING agonist-30 (compound 23: 20 µM: 5 h) increases TBK1 phosphorylation in wild-type HT1080 cells but not in HT1080

STING-KO cells^[1].

STING agonist-30 (20 μ M; 8 h) boosts interferon β (IFN β) and TNF- α expression^[1].

STING agonist-30 (0-20 μ M; 5 h) activates both mouse and human STING in a dose-dependent manner [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis $^{[1]}$

Cell Line:	HT1080, THP1, BMDMs and MEFs
Concentration:	2.5, 5, 10, and 20 μM
Incubation Time:	5 hours
Result:	Induced obvious dimeric STING bands.

REFERENCES

[1]. Zang R, et, al. Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist. Eur J Med Chem. 2023 Mar 15;250:115184.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA